CN111433213A - 作为Akt抑制剂的盐型及其晶型 - Google Patents

作为Akt抑制剂的盐型及其晶型 Download PDF

Info

Publication number
CN111433213A
CN111433213A CN201880078387.9A CN201880078387A CN111433213A CN 111433213 A CN111433213 A CN 111433213A CN 201880078387 A CN201880078387 A CN 201880078387A CN 111433213 A CN111433213 A CN 111433213A
Authority
CN
China
Prior art keywords
compound
formula
crystalline form
akt
stirring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880078387.9A
Other languages
English (en)
Other versions
CN111433213B (zh
Inventor
李刚
卢伦
陆青青
胡利红
丁照中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbin Zhenbao Pharmaceutical Co ltd
Original Assignee
Harbin Zhenbao Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbin Zhenbao Pharmaceutical Co ltd filed Critical Harbin Zhenbao Pharmaceutical Co ltd
Publication of CN111433213A publication Critical patent/CN111433213A/zh
Application granted granted Critical
Publication of CN111433213B publication Critical patent/CN111433213B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)

Abstract

一种作为Akt抑制剂的盐型及其晶型，具体涉及式(I)化合物的盐型及其晶型。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880078387.9A 2017-12-13 2018-12-12 作为Akt抑制剂的盐型及其晶型 Active CN111433213B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017113314481 2017-12-13
CN201711331448 2017-12-13
PCT/CN2018/120531 WO2019114741A1 (zh) 2017-12-13 2018-12-12 作为Akt抑制剂的盐型及其晶型

Publications (2)

Publication Number Publication Date
CN111433213A true CN111433213A (zh) 2020-07-17
CN111433213B CN111433213B (zh) 2023-03-10

Family

ID=66819227

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880078387.9A Active CN111433213B (zh) 2017-12-13 2018-12-12 作为Akt抑制剂的盐型及其晶型

Country Status (8)

Country Link
US (1) US11261196B2 (zh)
EP (1) EP3725791B1 (zh)
JP (1) JP7101781B2 (zh)
KR (1) KR102394934B1 (zh)
CN (1) CN111433213B (zh)
ES (1) ES2943092T3 (zh)
PT (1) PT3725791T (zh)
WO (1) WO2019114741A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022017448A1 (zh) * 2020-07-22 2022-01-27 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230321108A1 (en) * 2020-07-22 2023-10-12 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Unit dosage composition of akt inhibitor
WO2022121788A1 (zh) * 2020-12-07 2022-06-16 南京正大天晴制药有限公司 一种吡唑并氮杂卓类akt抑制剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1639151A (zh) * 2002-03-12 2005-07-13 霍夫曼-拉罗奇有限公司 新的氮杂环庚烷衍生物
WO2008065054A1 (en) * 2006-11-28 2008-06-05 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
EP2002836A1 (en) * 2007-05-31 2008-12-17 Nerviano Medical Sciences S.r.l. Cyclocondensed azaindoles active as kinase inhibitors
CN101646427A (zh) * 2007-02-07 2010-02-10 史密丝克莱恩比彻姆公司 Akt活性抑制剂
WO2017215588A1 (zh) * 2016-06-16 2017-12-21 南京明德新药研发股份有限公司 作为Akt抑制剂的二氢吡唑氮杂卓类化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1968568A4 (en) 2005-12-22 2011-04-13 Glaxosmithkline Llc HEMMER OF NUTS ACTIVITY
US20110129455A1 (en) 2008-06-26 2011-06-02 Hong Lin Inhibitors of akt activity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1639151A (zh) * 2002-03-12 2005-07-13 霍夫曼-拉罗奇有限公司 新的氮杂环庚烷衍生物
WO2008065054A1 (en) * 2006-11-28 2008-06-05 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
CN101646427A (zh) * 2007-02-07 2010-02-10 史密丝克莱恩比彻姆公司 Akt活性抑制剂
EP2002836A1 (en) * 2007-05-31 2008-12-17 Nerviano Medical Sciences S.r.l. Cyclocondensed azaindoles active as kinase inhibitors
WO2017215588A1 (zh) * 2016-06-16 2017-12-21 南京明德新药研发股份有限公司 作为Akt抑制剂的二氢吡唑氮杂卓类化合物
CN109311908A (zh) * 2016-06-16 2019-02-05 南京明德新药研发股份有限公司 作为Akt抑制剂的二氢吡唑氮杂卓类化合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022017448A1 (zh) * 2020-07-22 2022-01-27 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型
CN115843298A (zh) * 2020-07-22 2023-03-24 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型
CN115843298B (zh) * 2020-07-22 2024-03-29 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型

Also Published As

Publication number Publication date
JP7101781B2 (ja) 2022-07-15
PT3725791T (pt) 2023-04-04
EP3725791A1 (en) 2020-10-21
KR20200097771A (ko) 2020-08-19
EP3725791B1 (en) 2023-03-15
CN111433213B (zh) 2023-03-10
WO2019114741A1 (zh) 2019-06-20
JP2021508319A (ja) 2021-03-04
ES2943092T3 (es) 2023-06-08
EP3725791A4 (en) 2020-11-18
KR102394934B1 (ko) 2022-05-04
US20210087205A1 (en) 2021-03-25
US11261196B2 (en) 2022-03-01

Similar Documents

Publication Publication Date Title
CN111433213B (zh) 作为Akt抑制剂的盐型及其晶型
US11040979B2 (en) Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN109689641B (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
CN108239071B (zh) 酰胺及硫代酰胺类衍生物及其制备方法和应用
CN106565612B (zh) 二苯乙烯基嘧啶类化合物，组合物及其用途
EP4355350A1 (en) Stapled peptides and methods thereof
CN108101926B (zh) 含喹啉酮的嘧啶并五元杂环类化合物、制备方法及其应用
Mallikanti et al. Synthesis, antimicrobial activity and molecular docking of novel benzimidazole conjugated 1, 2, 3-triazole analogues
CN115836069B (zh) 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途
EP3805229B1 (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
CN114269723B (zh) 吡嗪-2(1h)-酮类化合物的d晶型及其制备方法
CN110256465B (zh) 一种含二氢吡喃并噻唑的2,4-二氨基嘧啶及其应用
CN109053594B (zh) 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN107383019A (zh) 吡唑并[4,3‑h]喹唑啉类化合物及其用途
CN115843298B (zh) 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型
CN113461661A (zh) 6-(吡啶-3-基)喹唑啉-4(3h)-酮类衍生物及其制备和应用
CN110041239B (zh) N-(苯甲酰基)-l-半胱氨酸甲酯类衍生物及其制备方法和用途
CN104910074A (zh) 一类含有羟肟酸基团的吡唑类衍生物及其制备方法及用途
CA3080827A1 (en) Salt form and crystal form of compound as fgfr4 inhibitor and preparation method thereof
CN111518078B (zh) 一种含氨基吡啶的嘧啶类化合物及其应用
CN111484505B (zh) 一种双环RORγ抑制剂的盐酸盐结晶型
US20240174681A1 (en) Salt and crystalline forms of fgfr4 inhibitor and uses thereof
CN113087708A (zh) 一种蝶啶酮类化合物及其应用
CN104945416B (zh) 一类螺异噁唑啉衍生物、其制备方法及医药用途
CN117567361A (zh) 一类芳基炔类化合物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant